title: Head-to-head or indirect comparisons of the novel oral anticoagulants in atrial fibrillation: what's next?
authors: Job
authors: J
authors: Harenberg
authors: Svetlana
authors: S
authors: Marx
authors: Martin
authors: M
authors: Wehling
mesh_terms: D000925:Anticoagulants / Q000627:therapeutic use*; D001281:Atrial Fibrillation / Q000188:drug therapy*; D001562:Benzimidazoles / Q000627:therapeutic use*; D017326:Clinical Trials, Phase III as Topic / Q000706:statistics & numerical data*; D000069604:Dabigatran; D005260:Female; D006801:Humans; D008297:Male; D009025:Morpholines / Q000627:therapeutic use*; D015337:Multicenter Studies as Topic / Q000706:statistics & numerical data*; D011720:Pyrazoles / Q000627:therapeutic use*; D011728:Pyridones / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic / Q000706:statistics & numerical data*; D000069552:Rivaroxaban; D013876:Thiophenes / Q000627:therapeutic use*; D019851:Thrombophilia / Q000188:drug therapy*; D015091:beta-Alanine / Q000031:analogs & derivatives* / Q000627:therapeutic use
chemical_list: D000925:Anticoagulants; D001562:Benzimidazoles; D009025:Morpholines; D011720:Pyrazoles; D011728:Pyridones; D013876:Thiophenes; D015091:beta-Alanine; C522181:apixaban; D000069552:Rivaroxaban; D000069604:Dabigatran